December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immutep Limited - American Depositary Shares (NQ:IMMP)

0.4180 +0.0025 (+0.60%)
Streaming Delayed Price Updated: 1:29 PM EDT, Mar 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Immutep Limited - American Depositary Shares

< Previous 1 2 3 4 Next >
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
From Immutep Limited
Via GlobeNewswire
News headline image
Cancer Focused Immutep's Stock Soars On Tuesday - Here's Why ↗
Immutep releases promising safety and efficacy data for 90mg eftilagimod alpha combined with paclitaxel in HR+/HER2- metastatic breast cancer. No serious adverse events were reported, and a 50% overall... 
Via Benzinga
News headline image
Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023
From Immutep Limited
Via GlobeNewswire
News headline image
Immutep’s Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer
From Immutep Limited
Via GlobeNewswire
News headline image
Immutep Touts Encouraging Data From Efti Triple Combination Therapy In Lung Cancer Setting ↗
 
Via Benzinga
News headline image
Maxim Group Maintains Buy Rating for Immutep: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
7 Stocks That Could Triple Your Money by 2024 ↗
If you want to get well ahead of the market and don’t mind the risk factor, check out these stocks to triple your money. 
Via InvestorPlace
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2023 ↗
 
Via Benzinga
News headline image
3 Best Penny Stocks Under $3 to Buy in June ↗
If you don’t mind the immense risks associated with high-potential opportunities, these best penny stocks under $3 could be for you. 
Via InvestorPlace
News headline image
Immutep Issues Development Update For Its Lead Cancer Candidate ↗
 
Via Benzinga
News headline image
Why Are Immutep Shares Trading Higher? ↗
Immutep Limited (NASDAQ: IMMP) has  
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Immutep Shares Spike As Cancer Tratement Shows Favorable Results In Phase 2 Trial ↗
Immutep Limited's (NASDAQ: IMMP) lead candidate — a soluble LAG-3 protein, in combination with Merck & Co Inc (NYSE: MRK) Keytruda (pembrolizumab) — 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Immutep’s Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer
From Immutep Limited
Via GlobeNewswire
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
We're starting off Wednesday with a look at the biggest pre-market stock movers traders will want to keep an eye on this morning! 
Via InvestorPlace
News headline image
Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha and Anti-PD-L1 Therapy BAVENCIO®
From Immutep Limited
Via GlobeNewswire
News headline image
7 Best Penny Stocks Under $3 to Buy in April ↗
If you have the audacity to consider ultra-speculative opportunities, these ideas for best penny stocks under $3 might be appealing. 
Via InvestorPlace
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
We're starting off the week with a breakdown of the biggest pre-market stock movers worth keeping an eye on Monday morning! 
Via InvestorPlace
News headline image
Why Did Immutep Ltd Stock Soar Recently?
Analysts and investors alike appear enamored with Immutep Ltd, whose earnings are growing; more of which could come from their latest product candidate. 
Via MarketBeat
Topics Initial Public Offering
News headline image
Immutep Enters into Second Clinical Trial Collaboration Agreement with Merck KGaA, Darmstadt, Germany, and Pfizer for New Combination Study of its First-in-Class LAG-3 Candidate, Eftilagimod Alpha, and Avelumab to Treat Urothelial Cancer
From Immutep Limited
Via GlobeNewswire
News headline image
Immutep Granted New Patents in Japan and South Korea for First-in-Class LAG-3 Candidate, Eftilagimod Alpha in Chemo-Immunotherapy Combination
From Immutep Limited
Via GlobeNewswire
News headline image
Why AeroClean Technologies Is Trading Higher By Over 39%; Here Are 26 Stocks Moving Premarket ↗
Gainers Bit Brother Limited (NASDAQ: BTB) rose 91.7% to $0.2150 in pre-market trading after declining around 14% on Monday. 
Via Benzinga
News headline image
Immutep's Lung Cancer Candidate Shows Encouraging Efficacy As Second-Line Treatment ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More ↗
Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks... 
Via Benzinga
News headline image
The Daily Biotech Pulse: SELLA In-licenses Oncology Asset, Merck's Pneumococcal Vaccine Review Extended, Arc Biopharma COVID Drug Flunks Mid-Stage Study ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More ↗
Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets. 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.